by Jason Heaviland | Feb 26, 2026
This publication from SynDevRx examines the dual anti-obesity and anti-tumor effects of Evexomostat (SDX-7320), a METAP2 inhibitor evaluated in diet-induced obese mouse and rat models. Using Next-Generation Metabolomics from Panome Bio, the study reveals distinct...
by Jason Heaviland | Oct 29, 2025
Advancing Animal Model Research with Multi-Omics Integration Discover how Panome Bio’s Next-Generation MetabolomicsTM and integrated multi-omics approaches enhance the translational value of animal model research. This application note demonstrates how comprehensive...
by ODWAdmin | Sep 18, 2025
Revolutionize Microbiome Research with Functional Analysis The gut microbiome, a community of microorganism, influences host digestion, immunity, neural signaling and metabolism. Discover how Next-Generation Metabolomics reveals microbiome functions and host...
by ODWAdmin | Jun 24, 2025
This study from researchers at MaineHealth utilized Next-Generation Metabolomics to identify a cardioprotective signature in mouse blood plasma, and activated mitochondrial activity and energy production in liver and brown adipose tissue.. Read the article now to find...
by ODWAdmin | Jan 23, 2025
Sex-Based Metabolomic Differences in Checkpoint Inhibitor Response This poster from our partners at TD2 (Translational Drug Development) highlights significant differences in tumor growth inhibition and treatment responses between obese and control diet-fed mice. Dive...
